Pharmafile Logo

dual tasking

- PMLiVE

Education, AI and More at ASH 2024

Medscape will showcase eight educational symposia and three posters at ASH 2024, highlighting advancements in hematology and oncology education. The presentations will reflect on the impact of last year's programs,...

Medscape Education

- PMLiVE

Novartis and Ratio enter radiotherapeutics partnership worth $745m

The companies will focus on advancing a candidate for SSTR2-expressing tumours

- PMLiVE

J&J and Protagonist share promising phase 3 results for icotrokinra in plaque psoriasis

More than 125 million people globally are estimated to be living with the skin disorder

- PMLiVE

FDA approves BridgeBio Pharma’s Attruby to treat rare heart disease ATTR-CM

Transthyretin amyloid cardiomyopathy affects up to 500,000 people worldwide

- PMLiVE

More is different

Don’t be simplistic with your complex problems

- PMLiVE

PMEA 2024: a celebration of excellence in pharmaceutical marketing

This year’s Awards, held at the Sheraton Grand in London, included 17 categories

- PMLiVE

Pfizer’s Hympavzi receives EC approval to treat haemophilia A and B patients

The genetic blood disorder affects more than 800,000 people globally

- PMLiVE

Innovative Trials celebrates success for its groundbreaking Retention Patch Program

Innovative Trials attended the PME Award Gala Dinner last night (21st November 2024)

Innovative Trials

Ki Park of Genesis Research Group

Genesis Research Group unveils enhanced US market access data analytics

Genesis Research Group (“Genesis”), a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the expansion of its real-world data analytics capabilities...

Genesis Research Group

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links